Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 08 07 2019
revised: 28 01 2020
accepted: 02 02 2020
pubmed: 9 2 2020
medline: 24 4 2021
entrez: 9 2 2020
Statut: ppublish

Résumé

The amylin receptor (AMY) and calcitonin receptor (CTR) agonists induce acute suppression of food intake in rodents by binding to receptors in the area postrema (AP) and potentially by targeting arcuate (ARC) neurons directly. Salmon calcitonin (sCT) induces more potent, longer lasting anorectic effects compared to amylin. We thus aimed to investigate whether AMY/CTR agonists target key neuronal populations in the ARC, and whether differing brain distribution patterns could mediate the observed differences in efficacy with sCT and amylin treatment. Brains were examined by whole brain 3D imaging and confocal microscopy following subcutaneous administration of fluorescently labelled peptides to mice. We found that sCT, but not amylin, internalizes into a subset of ARC NPY neurons, along with an unknown subset of ARC, AP and dorsal vagal motor nucleus cells. ARC POMC neurons were not targeted. Furthermore, amylin and sCT displayed similar distribution patterns binding to receptors in the AP, the organum vasculosum of the lamina terminalis (OVLT) and the ARC. Amylin distributed within the median eminence with only specs of sCT being present in this region, however amylin was only detectable 10 minutes after injection while sCT displayed a residence time of up to 2 hours post injection. We conclude that AMY/CTR agonists bind to receptors in a subset of ARC NPY neurons and in circumventricular organs. Furthermore, the more sustained and greater anorectic efficacy of sCT compared to rat amylin is not attributable to differences in brain distribution patterns but may more likely be explained by greater potency at both the CTR and AMY.

Identifiants

pubmed: 32035146
pii: S0028-3908(20)30053-8
doi: 10.1016/j.neuropharm.2020.107987
pii:
doi:

Substances chimiques

Calcium-Regulating Hormones and Agents 0
Neuropeptide Y 0
salmon calcitonin 7SFC6U2VI5
Calcitonin 9007-12-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107987

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest KR, LMJ, SL, TG and AS are full-time employees of Novo Nordisk and hold minor share portions as part of their employment. HLZ, JL, TL and CLF declare no competing financial interests.

Auteurs

Hannah Louise Zakariassen (HL)

Section of Experimental Animal Models, Department of Veterinary and Animal Science, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1871, Frederiksberg C, Denmark; Obesity Pharmacology, Novo Nordisk A/S, 2760, Måløv, Denmark.

Linu Mary John (LM)

Obesity Pharmacology, Novo Nordisk A/S, 2760, Måløv, Denmark.

Jens Lykkesfeldt (J)

Section of Experimental Animal Models, Department of Veterinary and Animal Science, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1871, Frederiksberg C, Denmark.

Kirsten Raun (K)

Obesity Pharmacology, Novo Nordisk A/S, 2760, Måløv, Denmark.

Tine Glendorf (T)

Diabetes Pharmacology 2, Novo Nordisk A/S, 2760, Måløv, Denmark.

Lauge Schaffer (L)

Research Chemistry, Novo Nordisk A/S, 2760, Måløv, Denmark.

Sofia Lundh (S)

Pathology and Imaging, Novo Nordisk A/S, 2760, Måløv, Denmark.

Anna Secher (A)

Diabetes Pharmacology 2, Novo Nordisk A/S, 2760, Måløv, Denmark.

Thomas Alexander Lutz (TA)

Institute of Veterinary Physiology, University of Zurich, CH-8057, Zurich, Switzerland.

Christelle Le Foll (C)

Institute of Veterinary Physiology, University of Zurich, CH-8057, Zurich, Switzerland. Electronic address: christelle.lefoll@uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH